Viewing data from:

TRI-SPRINTEC

ANDA

ETHINYL ESTRADIOL; NORGESTIMATE | A075808 | BARR LABORATORIES INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Tri-Sprintec (2023)

Total Spending

$330K

Total Claims

12,829

Beneficiaries

2,897

Avg Cost/Unit

$0.49

Spending Trend

$633K(2019)→$612K(2020)→$415K(2021)→$360K(2022)→$330K(2023)

YoY Change:+3.0%

5yr CAGR:-0.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG

0 patents0 exclusivities▴

TABLET;ORAL-28 | Approved: Dec 29, 2003

No patent or exclusivity listings for this strength.